CL2020002737A1 - Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769) - Google Patents

Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)

Info

Publication number
CL2020002737A1
CL2020002737A1 CL2020002737A CL2020002737A CL2020002737A1 CL 2020002737 A1 CL2020002737 A1 CL 2020002737A1 CL 2020002737 A CL2020002737 A CL 2020002737A CL 2020002737 A CL2020002737 A CL 2020002737A CL 2020002737 A1 CL2020002737 A1 CL 2020002737A1
Authority
CL
Chile
Prior art keywords
tils
methods
divisional application
expanding
tumor infiltrating
Prior art date
Application number
CL2020002737A
Other languages
English (en)
Inventor
Seth Wardell
James Bender
Michael T Lotze
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of CL2020002737A1 publication Critical patent/CL2020002737A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos para expandir TILs y producir poblaciones terapéuticas de TILs, incluyendo nuevos métodos para expandir las poblaciones de TILs en un sistema cerrado que llevan a una mayor eficacia, mayor fenotipo y mayor salud metabólica de los TILs en un período de tiempo más corto, mientras permite una contaminación microbiana reducida así como menores costos. Estos TILs se usan en regímenes de tratamiento terapéuticos.
CL2020002737A 2017-03-29 2020-10-22 Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769) CL2020002737A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762478506P 2017-03-29 2017-03-29
US201762539410P 2017-07-31 2017-07-31
US201762548306P 2017-08-21 2017-08-21
US201762554538P 2017-09-05 2017-09-05
US201762559374P 2017-09-15 2017-09-15
US201762567121P 2017-10-02 2017-10-02
US201762577655P 2017-10-26 2017-10-26
US201762582874P 2017-11-07 2017-11-07
US201762596374P 2017-12-08 2017-12-08

Publications (1)

Publication Number Publication Date
CL2020002737A1 true CL2020002737A1 (es) 2021-03-05

Family

ID=61569356

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002769A CL2019002769A1 (es) 2017-03-29 2019-09-27 Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia.
CL2020002737A CL2020002737A1 (es) 2017-03-29 2020-10-22 Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019002769A CL2019002769A1 (es) 2017-03-29 2019-09-27 Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia.

Country Status (36)

Country Link
US (60) US10894063B2 (es)
EP (6) EP3722415B1 (es)
JP (6) JP7169291B2 (es)
KR (2) KR102686794B1 (es)
CN (1) CN110785486A (es)
AU (2) AU2018243355B2 (es)
BR (1) BR112019020326A2 (es)
CA (1) CA3057975A1 (es)
CL (2) CL2019002769A1 (es)
CO (1) CO2019011995A2 (es)
CR (1) CR20190487A (es)
CY (1) CY1124136T1 (es)
DK (3) DK3730608T3 (es)
EC (1) ECSP19077884A (es)
ES (3) ES3009885T3 (es)
FI (2) FI3730608T3 (es)
HR (3) HRP20250068T1 (es)
HU (3) HUE070176T2 (es)
IL (2) IL305198A (es)
JO (1) JOP20190224A1 (es)
LT (3) LT3730608T (es)
MA (2) MA68856B1 (es)
MD (3) MD3730608T2 (es)
MX (2) MX2019011768A (es)
NZ (1) NZ796142A (es)
PE (1) PE20191841A1 (es)
PH (1) PH12019502247A1 (es)
PL (3) PL3722415T3 (es)
PT (3) PT3730608T (es)
RS (3) RS66452B1 (es)
SG (1) SG11201908994RA (es)
SI (3) SI3730608T1 (es)
SM (3) SMT202100298T1 (es)
TN (1) TN2019000273A1 (es)
TW (1) TWI799402B (es)
WO (1) WO2018182817A1 (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014133568A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
SMT202400133T1 (it) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimolazione di linfociti infiltranti il tumore crioconservati
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
ES3055314T3 (en) 2017-01-06 2026-02-11 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AR112072A1 (es) * 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CN111601883B (zh) * 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12104172B2 (en) 2018-01-08 2024-10-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
JP2021518160A (ja) 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
AU2019236204B2 (en) 2018-03-15 2026-02-26 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
MA52667B1 (fr) * 2018-03-29 2024-07-31 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
MA52533A (fr) * 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
WO2019217753A1 (en) * 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR112021007115A2 (pt) 2018-10-15 2021-07-20 Nurix Therapeutics, Inc. compostos bifuncionais para dedradação de btk por meio da via de proteossoma de ubiquitina
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP7688575B2 (ja) * 2018-11-05 2025-06-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
US20230039976A1 (en) * 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
KR20210091213A (ko) * 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
CN113423820A (zh) * 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
US20220193131A1 (en) * 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
EP3908678A1 (en) 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
US20220257656A1 (en) * 2019-07-10 2022-08-18 National Cancer Center Specific marker for identifying t cells specifically attacking cancer cells
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US20220273717A1 (en) * 2019-08-12 2022-09-01 Bellicum Pharmaceuticals, Inc. Improved formulations for immune cells
JP7764035B2 (ja) 2019-08-19 2025-11-05 ウニベルシテート バーゼル 細胞治療の方法
KR20220068227A (ko) * 2019-09-24 2022-05-25 누릭스 테라퓨틱스 인코포레이티드 입양 세포 요법에 사용하기 위한 cbl 억제제 및 조성물
EP4048295A1 (en) * 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP7749561B2 (ja) * 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023524639A (ja) * 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法
EP4143300A1 (en) 2020-04-28 2023-03-08 Lyell Immunopharma, Inc. Methods for culturing cells
CA3176654A1 (en) 2020-04-28 2021-11-04 Karl PEGGS T cell therapy
JP2023524032A (ja) * 2020-04-30 2023-06-08 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート ネオアンチゲン情報に基づいた腫瘍浸潤性リンパ球によるがん免疫療法
TW202208616A (zh) * 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
EP4159843A4 (en) * 2020-05-29 2024-07-31 Shanghai Juncell Therapeutics Co., Ltd. MEDIUM FOR SEEDING CELLS OF TUMOR INFILTRATING LYMPHOCYTES AND ITS APPLICATION
CN111876381A (zh) * 2020-07-22 2020-11-03 中美冠科生物技术（太仓）有限公司 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) * 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023550490A (ja) 2020-11-23 2023-12-01 ライエル・イミュノファーマ・インコーポレイテッド 免疫細胞を培養するための方法
EP4252754A4 (en) 2020-11-25 2024-11-13 Shanghai Juncell Therapeutics Co., Ltd. PHARMACEUTICAL COMPOSITION FOR IMPROVING CELL KILLING AND USE THEREOF
EP4253530A4 (en) 2020-11-25 2024-10-30 Shanghai Juncell Therapeutics Co., Ltd. TUMOR INFILTRATION LYMPHOCYTE CULTURE MEDIUM AND ITS APPLICATION
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
WO2022133140A1 (en) * 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022130017A2 (en) * 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4263807A2 (en) * 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
TW202242085A (zh) 2020-12-31 2022-11-01 美商艾歐凡斯生物治療公司 供自動生產腫瘤浸潤淋巴球的裝置和方法
JPWO2022145490A1 (es) * 2021-01-04 2022-07-07
TW202241508A (zh) * 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
EP4298208A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
US20240191191A1 (en) * 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
KR20240032711A (ko) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물
KR102666931B1 (ko) * 2021-03-30 2024-05-20 주식회사 네오젠티씨 면역세포 조성물을 생산하는 방법
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
TW202309269A (zh) 2021-04-27 2023-03-01 日商武田藥品工業股份有限公司 重組抗原呈現細胞
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
DE102021002748A1 (de) 2021-05-27 2022-12-01 Zellwerk Gmbh Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren
WO2022263673A1 (en) * 2021-06-17 2022-12-22 CBio A/S Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
JP2024524185A (ja) 2021-06-22 2024-07-05 アキレス セラピューティクス ユーケー リミテッド 抗原特異的ｔ細胞を生成するための方法
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
US20240424097A1 (en) 2021-09-09 2024-12-26 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
JP2024534581A (ja) 2021-09-24 2024-09-20 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤
KR20240090898A (ko) 2021-10-26 2024-06-21 누릭스 테라퓨틱스 인코포레이티드 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
IL312027A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing immune cells
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
CA3243416A1 (en) * 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
US20250099588A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CA3247638A1 (en) 2022-04-06 2023-10-12 Maria Fardis TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
CA3248034A1 (en) * 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
JP2025531877A (ja) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
US12181192B2 (en) * 2022-09-16 2024-12-31 Black & Decker, Inc. Methods and devices for controlling the temperature of a surface
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
JP2025537155A (ja) 2022-11-04 2025-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
CN120225666A (zh) 2022-11-21 2025-06-27 艾欧凡斯生物治疗公司 用于评估基因编辑的t细胞的增殖效力的方法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
DE102023002417B3 (de) 2023-06-15 2024-12-05 Zellwerk Gmbh Verfahren zur Expansion von Zellen
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025038289A1 (en) * 2023-08-17 2025-02-20 H. Lee Moffitt Cancer Center And Research Institute Inc. Using 12 chemokine signature to select sting agonist and til treatments for solid tumors
WO2025047660A1 (ja) * 2023-08-31 2025-03-06 国立大学法人筑波大学 腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞を定量する方法、腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞をスクリーニングする方法、治療用組成物、及びキット
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
CN118710478B (zh) * 2024-08-27 2025-01-03 福州大学 基于改进麻雀搜索算法的地铁突发运营中断客流疏运方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1539929B1 (en) 2002-06-28 2013-04-10 Life Technologies Corporation Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1545204B1 (en) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ITMI20022118A1 (it) 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
EP2336293B1 (en) 2003-10-08 2016-02-10 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007071388A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
WO2007071390A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
WO2007071409A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating colon cancer
JP5205275B2 (ja) 2005-12-21 2013-06-05 セントクローネ インターナショナル エービー 散在性ガンの治療法
FR2911346B1 (fr) * 2007-01-12 2012-12-07 Ct Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
JP2014514927A (ja) 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
ES2598055T3 (es) * 2011-10-21 2017-01-25 Cell Medica Limited Dispositivo para la expansión aséptica de células
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN102816734A (zh) 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
AU2013262485B2 (en) 2012-05-18 2017-12-14 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
IL288241B2 (en) 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
EP2925329B1 (en) 2012-11-27 2021-01-06 Borrello, Ivan Marques Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
AU2013379772B2 (en) 2013-03-01 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive T cells from tumor
WO2014133568A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
JP6560667B2 (ja) 2013-06-24 2019-08-14 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 気体透過性細胞培養作業のための閉鎖系装置および方法
EP3022294B1 (en) * 2013-07-15 2019-11-20 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of preparing anti-human papillomavirus antigen t cells
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
KR20230085225A (ko) 2014-03-20 2023-06-13 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 입양 세포 요법을 위한 종양-침윤 림프구
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
ES2995052T3 (en) 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EP3838288A1 (en) 2014-06-11 2021-06-23 polybiocept GmbH Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
AU2016258845B2 (en) 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
WO2017048614A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US20190062706A1 (en) 2015-10-28 2019-02-28 Life Technologies As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
EP3487990A4 (en) 2016-06-28 2020-07-29 Geneius Biotechnology, Inc. T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
CN106244538A (zh) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 一种恶性腹水来源的til细胞的分离培养方法
LT3512547T (lt) 2016-09-14 2021-01-11 Abbvie Biotherapeutics Inc. Antikūnai prieš pd-1
SMT202400133T1 (it) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimolazione di linfociti infiltranti il tumore crioconservati
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46916A (fr) 2016-11-17 2019-09-25 Iovance Biotherapeutics Inc Resttumorinfiltrierende lymphozyten und verfahren zur herstellung und verwendung davon
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
CN106591232A (zh) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 一种高效的pd‑1‑cd8+t细胞的培养方法
ES3055314T3 (en) 2017-01-06 2026-02-11 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JP7780248B2 (ja) 2017-01-06 2025-12-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
JP7359751B2 (ja) 2017-03-14 2023-10-11 ジュノー セラピューティクス インコーポレイテッド 極低温保管のための方法
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
JP7349365B2 (ja) 2017-05-10 2023-09-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CN107384867B (zh) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 一种肿瘤组织til细胞制备方法及专用培养基
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
JP2023524639A (ja) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法

Also Published As

Publication number Publication date
US20220000924A1 (en) 2022-01-06
MX2019011768A (es) 2019-12-09
US11083752B2 (en) 2021-08-10
US20210128624A1 (en) 2021-05-06
US11241456B2 (en) 2022-02-08
US20200289569A1 (en) 2020-09-17
JP7169291B2 (ja) 2022-11-10
US20210128620A1 (en) 2021-05-06
US20200281978A1 (en) 2020-09-10
KR20240114787A (ko) 2024-07-24
US11168304B2 (en) 2021-11-09
CR20190487A (es) 2020-03-17
US20250082683A1 (en) 2025-03-13
NZ796142A (en) 2026-01-30
LT3730608T (lt) 2024-12-27
US11007225B1 (en) 2021-05-18
US11998568B2 (en) 2024-06-04
JP2020515257A (ja) 2020-05-28
JP2021519582A (ja) 2021-08-12
US10933094B2 (en) 2021-03-02
HRP20241688T1 (hr) 2025-02-14
US11007226B2 (en) 2021-05-18
PE20191841A1 (es) 2019-12-31
US20190000883A1 (en) 2019-01-03
US10653723B1 (en) 2020-05-19
US20200306307A1 (en) 2020-10-01
US12121541B2 (en) 2024-10-22
US20250121009A1 (en) 2025-04-17
IL305198A (en) 2023-10-01
US10946045B2 (en) 2021-03-16
US20210106625A1 (en) 2021-04-15
SG11201908994RA (en) 2019-10-30
DK3730608T3 (da) 2024-12-16
US20210128623A1 (en) 2021-05-06
US10130659B2 (en) 2018-11-20
PL3601533T3 (pl) 2021-08-16
US20210361713A1 (en) 2021-11-25
US20220008469A1 (en) 2022-01-13
US20190083538A1 (en) 2019-03-21
JP2023012510A (ja) 2023-01-25
US20190070222A1 (en) 2019-03-07
US12194061B2 (en) 2025-01-14
US20210214685A1 (en) 2021-07-15
LT3722415T (lt) 2025-01-10
US10953047B2 (en) 2021-03-23
HUE070176T2 (hu) 2025-05-28
JP7817138B2 (ja) 2026-02-18
MD3730608T2 (ro) 2025-03-31
US10894063B2 (en) 2021-01-19
US20220387497A1 (en) 2022-12-08
RS66452B1 (sr) 2025-02-28
US20230012086A1 (en) 2023-01-12
PT3601533T (pt) 2021-05-24
US10953046B2 (en) 2021-03-23
US10905718B2 (en) 2021-02-02
SMT202500040T1 (it) 2025-03-12
TWI799402B (zh) 2023-04-21
US20200276242A1 (en) 2020-09-03
US11541077B2 (en) 2023-01-03
ES3009885T3 (en) 2025-03-31
MX2024002827A (es) 2024-03-19
CL2019002769A1 (es) 2020-05-08
US10646517B2 (en) 2020-05-12
FI3722415T3 (fi) 2025-01-10
EP3910055A1 (en) 2021-11-17
US11040070B2 (en) 2021-06-22
US11202803B1 (en) 2021-12-21
FI3730608T3 (fi) 2024-12-30
JP7522037B2 (ja) 2024-07-24
US10695372B2 (en) 2020-06-30
US10925900B2 (en) 2021-02-23
MA68856B1 (fr) 2025-01-31
US12558375B2 (en) 2026-02-24
EP3766964A1 (en) 2021-01-20
PL3730608T3 (pl) 2025-03-31
LT3601533T (lt) 2021-06-10
AU2018243355B2 (en) 2024-10-24
US20180207201A1 (en) 2018-07-26
US20200155601A1 (en) 2020-05-21
CA3057975A1 (en) 2018-10-04
ECSP19077884A (es) 2020-01-31
PT3722415T (pt) 2025-01-08
US20190358260A1 (en) 2019-11-28
EP3722415B1 (en) 2024-11-06
ES2874335T3 (es) 2021-11-04
SI3601533T1 (sl) 2021-09-30
US10537595B2 (en) 2020-01-21
SI3730608T1 (sl) 2025-03-31
SI3722415T1 (sl) 2025-03-31
US11337998B2 (en) 2022-05-24
EP4279574A2 (en) 2023-11-22
JP2023011778A (ja) 2023-01-24
CY1124136T1 (el) 2022-05-27
JP7814287B2 (ja) 2026-02-16
BR112019020326A2 (pt) 2020-04-28
US10166257B2 (en) 2019-01-01
US10420799B2 (en) 2019-09-24
US20180325954A1 (en) 2018-11-15
MD3601533T2 (ro) 2021-07-31
US10363273B2 (en) 2019-07-30
US11052115B2 (en) 2021-07-06
US20220378838A1 (en) 2022-12-01
US20210128622A1 (en) 2021-05-06
US20210207092A1 (en) 2021-07-08
US11344579B2 (en) 2022-05-31
MD3722415T2 (ro) 2025-05-31
US11202804B2 (en) 2021-12-21
US20200246384A1 (en) 2020-08-06
US11304979B2 (en) 2022-04-19
US12226434B2 (en) 2025-02-18
US20180280436A1 (en) 2018-10-04
US20220000923A1 (en) 2022-01-06
HRP20250068T1 (hr) 2025-03-14
US20220387495A1 (en) 2022-12-08
US11517592B1 (en) 2022-12-06
US20220387499A1 (en) 2022-12-08
US20180282694A1 (en) 2018-10-04
US20210100842A1 (en) 2021-04-08
US20190358261A1 (en) 2019-11-28
US20220395533A1 (en) 2022-12-15
US20190000882A1 (en) 2019-01-03
PT3730608T (pt) 2025-01-07
JP7772680B2 (ja) 2025-11-18
JP2025023951A (ja) 2025-02-19
TN2019000273A1 (en) 2021-01-07
US20210361712A1 (en) 2021-11-25
EP3730608A1 (en) 2020-10-28
CN110785486A (zh) 2020-02-11
EP4279574A3 (en) 2024-04-10
WO2018182817A1 (en) 2018-10-04
HRP20210677T1 (hr) 2021-06-25
RS66400B1 (sr) 2025-02-28
US20230045899A1 (en) 2023-02-16
JOP20190224A1 (ar) 2019-09-26
DK3601533T3 (da) 2021-05-03
EP3601533A1 (en) 2020-02-05
US20210100843A1 (en) 2021-04-08
US20230015649A1 (en) 2023-01-19
DK3722415T3 (da) 2025-01-13
IL269543A (en) 2019-11-28
US20220000925A1 (en) 2022-01-06
US20210128625A1 (en) 2021-05-06
HUE070256T2 (hu) 2025-05-28
US20210137984A1 (en) 2021-05-13
MA68598B1 (fr) 2025-01-31
EP3722415A1 (en) 2020-10-14
US10463697B2 (en) 2019-11-05
NZ758201A (en) 2024-01-26
US20220387496A1 (en) 2022-12-08
US20220387498A1 (en) 2022-12-08
KR20190142342A (ko) 2019-12-26
US20200306306A1 (en) 2020-10-01
RS61863B1 (sr) 2021-06-30
TW201839129A (zh) 2018-11-01
AU2025200434A1 (en) 2025-02-20
US10639330B2 (en) 2020-05-05
SMT202100298T1 (it) 2021-07-12
US11052116B2 (en) 2021-07-06
US20210207091A1 (en) 2021-07-08
US11013770B1 (en) 2021-05-25
PH12019502247A1 (en) 2020-06-29
US20210079348A1 (en) 2021-03-18
US20210128621A1 (en) 2021-05-06
US20210353677A1 (en) 2021-11-18
US20210379111A1 (en) 2021-12-09
ES3008832T3 (en) 2025-03-25
HUE054829T2 (hu) 2021-10-28
US20190083536A1 (en) 2019-03-21
US20200276241A1 (en) 2020-09-03
US11273180B2 (en) 2022-03-15
US10272113B2 (en) 2019-04-30
US20220387494A1 (en) 2022-12-08
SMT202500027T1 (it) 2025-03-12
US20220362301A1 (en) 2022-11-17
JP2023012511A (ja) 2023-01-25
US20230133298A1 (en) 2023-05-04
KR102686794B1 (ko) 2024-07-24
US12485145B2 (en) 2025-12-02
US11291687B2 (en) 2022-04-05
US11273181B2 (en) 2022-03-15
PL3722415T3 (pl) 2025-03-31
US11168303B2 (en) 2021-11-09
US10918666B2 (en) 2021-02-16
US20250121008A1 (en) 2025-04-17
EP3601533B1 (en) 2021-02-24
AU2018243355A1 (en) 2019-10-31
US10946044B2 (en) 2021-03-16
US20190083539A1 (en) 2019-03-21
US10398734B2 (en) 2019-09-03
US20190358259A1 (en) 2019-11-28
US11529372B1 (en) 2022-12-20
EP3730608B1 (en) 2024-10-23
CO2019011995A2 (es) 2020-02-18

Similar Documents

Publication Publication Date Title
CL2020002737A1 (es) Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)
MX2021005216A (es) Procesos para la produccion de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
MX2020011134A (es) Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
MX2020010264A (es) Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia.
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
BR112018008915A2 (pt) aparelho ortodôntico com memória de formato contínuo
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
AR126650A2 (es) Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
MX2021004383A (es) Composiciones y metodos para la estimulacion ovarica controlada.
AR110733A1 (es) Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
AR119647A1 (es) Edición de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
AR122009A1 (es) Procesos para producción de linfocitos infiltrantes del tumor y usos de los mismos en inmunoterapia
MY200434A (en) Compositions and methods for the treatment of sinus disease and disorders
UA112357C2 (uk) Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи
EA202191275A1 (ru) Способы получения инфильтрующих опухоли лимфоцитов и варианты их применения в иммунотерапии
UA125728U (uk) Спосіб лікування атопічного дерматиту
UA128597U (uk) Спосіб лікування цереброваскулярних порушень головного мозку
UA130638U (uk) Спосіб природного омолодження організму людини
UA97357U (en) Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA98863U (en) Method for treating endometrial hyperplasia of patients of reproductive age
RU2014116784A (ru) Способ лечения заболеваний пародонта